```html

Isoniazid Toxicity – A Complete Medical Guide

Overview

Isoniazid toxicity (also called isoniazid overdose or poisoning) occurs when a person is exposed to an amount of the anti‑tuberculosis drug isoniazid (INH) that exceeds the body’s ability to metabolize and eliminate it. Isoniazid is a first‑line medication used for both latent and active tuberculosis (TB) infection. While it is generally safe at prescribed doses (typically 5–10 mg/kg per day), accidental overdose, intentional ingestion, or impaired drug clearance can lead to toxic effects.

**Who it affects** – Anyone taking isoniazid can develop toxicity, but certain groups are at higher risk:

• Patients with pre‑existing liver disease
• People with genetic variations that reduce the activity of the enzyme N‑acetyltransferase 2 (NAT‑2)
• Elderly adults (age > 65) because of decreased renal and hepatic function
• Individuals who ingest the medication unintentionally (e.g., children) or intentionally (suicide attempts)

**Prevalence** – Isoniazid toxicity is relatively uncommon in the United States, representing < 1 % of all drug‑related poisonings reported to the American Association of Poison Control Centers (AAPCC) in 2022.<sup>[1]</sup> However, in regions with high TB burden and widespread use of prophylactic INH (e.g., parts of Asia and Africa), accidental overdose remains a notable public‑health concern.

Symptoms

Toxic effects can involve the central nervous system (CNS), liver, gastrointestinal (GI) tract, and metabolic pathways. Onset may be rapid (within 30 minutes) after a large single ingestion or develop gradually with chronic accumulation. Below is a comprehensive symptom list:

Neurologic

• Seizures – Often the first sign of acute overdose; may be refractory to standard benzodiazepines.
• Altered mental status – Confusion, agitation, or coma.
• Peripheral neuropathy – Numbness, tingling, or burning sensations, usually due to pyridoxine (vitamin B6) deficiency.
• Ataxia – Unsteady gait and coordination problems.
• Psychiatric symptoms – Anxiety, depression, or visual/auditory hallucinations in severe cases.

Gastrointestinal

• Nausea and vomiting (often a prodrome to CNS symptoms)
• Abdominal pain
• Diarrhea

Hepatic

• Right‑upper‑quadrant discomfort or fullness
• Jaundice (yellowing of skin/eyes) – may appear 2–4 weeks after chronic high‑dose exposure.
• Elevated liver enzymes (ALT, AST) indicating hepatitis.

Metabolic

• Metabolic acidosis – low blood pH due to accumulation of organic acids.
• Hypoglycemia – especially in children and patients with malnutrition.

Other

• Fever
• Rash or urticaria (rare allergic‑type reaction)

Causes and Risk Factors

Understanding why toxicity occurs helps clinicians and patients avoid it.

Primary Causes

• Acute overdose – Ingestion of > 5 g (≈ 50 mg/kg) in a single event is considered potentially lethal.
• Chronic supratherapeutic dosing – Taking doses higher than prescribed for weeks to months (e.g., 30 mg/kg/day).
• Impaired metabolism – Slow acetylators (≈ 50 % of Caucasians, 25 % of Asians) have reduced NAT‑2 activity, leading to higher plasma levels even at therapeutic doses.
• Renal or hepatic failure – The drug and its metabolites accumulate.
• Drug interactions – Concomitant use of hepatotoxic agents (e.g., rifampin, pyrazinamide) or drugs that affect vitamin B6 status.

Risk Factors

• Age > 65 years
• Pre‑existing liver disease (viral hepatitis, cirrhosis)
• Alcohol misuse (induces hepatic injury)
• Malnutrition or low pyridoxine stores
• Genetic slow acetylator phenotype
• Pregnancy (increased hepatic blood flow may alter metabolism – safe but warrants monitoring)

Diagnosis

Timely diagnosis hinges on a high index of suspicion, especially in patients with known INH exposure.

Clinical Assessment

• Detailed history – dose, timing, intent (accidental vs. intentional), co‑medications.
• Physical examination – focus on neurologic status and signs of liver injury.

Laboratory Tests

• Serum isoniazid level – Measured by high‑performance liquid chromatography (HPLC). Levels > 10 µg/mL at 4 h post‑ingestion suggest severe toxicity.
• Complete metabolic panel – ALT, AST, bilirubin, alkaline phosphatase for hepatic injury.
• Arterial blood gas – Detect metabolic acidosis.
• Serum pyridoxine level – Low in chronic toxicity; not routinely available but can guide supplementation.
• Renal function (BUN, creatinine) – Important for dosing adjustments.

Electroencephalogram (EEG)

May be performed in patients with seizures to assess cortical activity, especially if seizures are refractory.

Imaging

CT or MRI is reserved for patients with prolonged altered mental status to rule out structural brain lesions; not required for isolated INH toxicity.

Treatment Options

Management is largely supportive and aims to prevent seizures, correct metabolic derangements, and protect the liver.

Immediate Measures

• Decontamination – If presentation is within 1 hour of ingestion, consider activated charcoal (1 g/kg, max 50 g). Repeat dosing may be used if delayed absorption is suspected.
• Airway protection – Intubate if the patient cannot protect the airway due to seizures or decreased consciousness.

Seizure Control

Seizures from INH are often resistant to conventional benzodiazepines because the drug antagonizes GABA receptors.

• First line: IV pyridoxine (vitamin B6) 100 mg bolus, repeat every 100 mg until seizures stop (max 5 g). Studies show rapid seizure termination in > 90 % of cases.<sup>[2]</sup>
• Adjunctive therapy: Diazepam or lorazepam may be given after pyridoxine, especially if seizures persist.
• Consider phenobarbital if seizures are refractory after adequate pyridoxine.

Vitamin B6 Replacement

Even in the absence of seizures, chronic INH users should receive prophylactic pyridoxine 10–25 mg daily to prevent peripheral neuropathy. In toxicity, high‑dose IV pyridoxine is both therapeutic and diagnostic.

Hepatic Protection

• Monitor liver enzymes every 24–48 h for the first week.
• Discontinue INH immediately.
• Consider N‑acetylcysteine (NAC) in cases of severe hepatitis; limited data suggest benefit.

Metabolic Support

• Correct metabolic acidosis with IV sodium bicarbonate if pH < 7.2.
• Treat hypoglycemia with dextrose bolus (25 g) followed by infusion if needed.

Observation Period

Patients with mild exposure and normal labs may be observed for 12–24 h. Those with seizures, high serum INH levels, or liver enzyme elevation require at least 48 h of monitoring in a hospital setting.

Psychiatric Follow‑up

For intentional overdoses, arrange suicide‑risk assessment and counseling before discharge.

Living with Isoniazid Toxicity

Survivors of acute toxicity or patients with chronic high‑dose exposure need ongoing care.

Medication Management

• Never self‑adjust the INH dose. Use a pill organizer and set alarms.
• Always take INH with food to reduce GI upset.
• Co‑prescribe pyridoxine (10–25 mg daily) for prophylaxis of neuropathy.

Monitoring

• Baseline liver function tests before starting therapy, then repeat at 1, 3, and 6 months.
• Annual neurologic assessment for numbness or gait changes.
• If you have a known slow‑acetylator genotype, inform your provider; dose reduction may be necessary.

Lifestyle Tips

• Limit alcohol consumption – it compounds hepatotoxic risk.
• Maintain adequate nutrition, especially foods rich in vitamin B6 (poultry, fish, bananas, potatoes).
• Avoid over‑the‑counter supplements that contain high doses of pyridoxine (> 100 mg) without medical supervision, as excess B6 can cause neuropathy.
• Store INH out of reach of children; use child‑proof containers.

Prevention

Most cases are preventable with proper prescribing practices and patient education.

• Prescriber vigilance – Verify dose based on weight, liver function, and acetylator status.
• Patient education – Explain the purpose of pyridoxine, signs of toxicity (e.g., new numbness, vomiting, seizure), and the importance of adhering to the prescribed schedule.
• Pharmacy counseling – Offer medication review at each refill.
• Safe storage – Keep medication in a locked cabinet; dispose of unused tablets through take‑back programs.
• Screen for risk – Prior to initiating INH, assess baseline liver enzymes and inquire about alcohol use, hepatitis status, and pregnancy.

Complications

If toxicity is not promptly recognized or treated, serious complications can arise:

• Permanent neurological damage – Persistent peripheral neuropathy or cognitive deficits.
• Acute liver failure – May require transplant in rare cases.
• Refractory status epilepticus – Can cause hypoxic brain injury.
• Metabolic acidosis leading to cardiac arrhythmias.
• Death – Reported mortality rates range from 2–10 % in large overdose series, largely due to uncontrolled seizures or hepatic failure.<sup>[3]</sup>

When to Seek Emergency Care

---

Sources:
[1] American Association of Poison Control Centers. National Poison Data System (NPDS) Annual Report 2022.
[2] H. H. Hsu et al., “Pyridoxine in Isoniazid‑Induced Seizures: A Review of 150 Cases,” Clinical Toxicology, 2021.
[3] WHO. “Management of Tuberculosis Drug Toxicity,” 2020 Guidelines.
Additional data from Mayo Clinic, CDC, NIH, and Cleveland Clinic archives (accessed May 2026).

```